CDRI 97/78
Alternative Names: 97/78; CDRI-97/78; CDRI-9778; Compound 97/78Latest Information Update: 04 Apr 2023
At a glance
- Originator Central Drug Research Institute
- Developer Central Drug Research Institute; Ipca Laboratories
- Class Antimalarials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 22 Feb 2023 Discontinued - Phase-I for Malaria (In volunteers) in India (PO)
- 22 Feb 2023 Discontinued - Preclinical for Malaria in India (Parenteral)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Malaria(In volunteers) in India (PO)